Mesa Laboratories, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 9, 2026, reporting second-quarter and first-half financial results for fiscal year 2027.

Key Highlights

  • Quarterly revenue of $62,336 thousand: revenues for the three months ended September 30, 2026 rose from $60,737 thousand in the same period a year earlier, according to the filing.
  • Net income of $4,341 thousand for Q2: compared with $2,476 thousand in the prior-year quarter, with diluted earnings per share of $0.75 versus $0.45.
  • Six-month revenues of $122,474 thousand: up from $120,280 thousand in the first half of the prior fiscal year, with net income of $7,171 thousand.
  • Total debt reduced: the revolving line of credit stood at $67,250 thousand at September 30, 2026, down from $84,500 thousand at March 31, 2026, with the combined term loan and revolver totaling approximately $131,506 thousand.
  • Total stockholders' equity increased to $194,596 thousand: up from $186,245 thousand at March 31, 2026, as reported on the condensed consolidated balance sheet.
  • Dividends of $0.16 per share were paid in each of the two quarters covered by the filing period.
  • Shares outstanding of 5,620,520 as of November 2, 2026, with 5,613,964 shares issued and outstanding as of September 30, 2026.

Mesa Laboratories Financial Results for the Quarter Ended September 30, 2026

According to the filing, Mesa Laboratories, Inc. (NASDAQ:MLAB) reported revenues of $62,336 thousand for the three months ended September 30, 2026, compared with $60,737 thousand in the same quarter of the prior year. Gross profit for the quarter was $39,878 thousand, up from $37,331 thousand a year earlier. Operating income reached $8,388 thousand, compared with $4,724 thousand in the prior-year period. The company reported net income of $4,341 thousand, with basic earnings per share of $0.77 and diluted earnings per share of $0.75.

For the six months ended September 30, 2026, the filing disclosed revenues of $122,474 thousand and net income of $7,171 thousand, compared with revenues of $120,280 thousand and net income of $7,218 thousand for the same period in the prior year. Total operating expenses for the six-month period were $63,471 thousand, down from $66,482 thousand in the year-earlier period. Interest expense and amortization of debt issuance costs for the six months were $4,500 thousand, compared with $5,060 thousand previously, reflecting the company's reduced debt balance as the revolving line of credit declined from $84,500 thousand to $67,250 thousand over the period.

The condensed consolidated balance sheet as of September 30, 2026 showed total assets of $407,735 thousand and total liabilities of $213,139 thousand. Goodwill stood at $185,236 thousand, and the accumulated deficit narrowed to $180,358 thousand from $185,747 thousand at March 31, 2026. Cash and cash equivalents were $22,312 thousand at quarter end. Stock-based compensation expense for the six-month period was $5,736 thousand, as disclosed in the cash flow statement.

What Was Disclosed

Mesa Laboratories filed its quarterly report covering the three and six months ended September 30, 2026, disclosing revenue growth, improved operating income, reduced revolving credit borrowings, and an increase in total stockholders' equity relative to the prior fiscal year-end.